Topic: Risk factors - Primary Care
Monday, 12 September 2016
Two injectable antibody-based therapies inhibiting the activity of PCSK9 - alirocumab and evolucumab - have recently been licensed. This paper reviews the current status of lipid management, the actions of PCSK9, and the clinical trial results achieved with PCSK9 inhibitors in early studies.
Tuesday, 02 October 2018
This article reviews the important and growing role of the NHS Health Check in tackling some of the challenges in prevention and treatment of CVD and other non-communicable diseases.